Subscribe

Shitanshu Uppal

ICON8: Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian Cancer (Primary PFS Analysis)

Weekly dose-dense chemotherapy does not significantly improve progression-free survival compared to standard 3-weekly chemotherapy in a predominantly European population.

PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Niraparib significantly extends progression-free survival among patients with newly diagnosed advanced ovarian cancer post-response to platinum-based chemotherapy, regardless of homologous-recombination deficiency status.

Publications Update # 50

GYOEDU updates, women's leadership programs, SHAPE trial, CONCERV and bowel surgery - staplers

SHAPE: Simple vs. Radical Hysterectomy for Low-Risk Early-Stage Cervical Cancer

Simple hysterectomy is not inferior to radical hysterectomy in terms of the 3-year incidence of pelvic recurrence and presents a lower risk of urinary complications.

PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

The addition of maintenance olaparib with bevacizumab significantly improves progression-free survival, especially in patients with HRD-positive tumors, including those without a BRCA mutation.

GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer

The TC regimen demonstrated noninferiority to TAP in terms of OS and PFS while offering a better toxicity profile, making it a suitable first-line treatment for advanced endometrial cancer

KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Pembrolizumab significantly improves PFS and OS in PD-L1–positive persistent, recurrent, or metastatic cervical cancer patients when added to standard chemotherapy, with or without bevacizumab, maintaining a manageable safety profile.

GYOEDU One-on-One Coaching and Mentorship

GYOEDU's unique program blends mentorship with executive coaching

Navigation Help

Welcome

Sarcoma Trials

List of key sarcoma trials